Tefina, a 'female Viagra', currently being studied

Tefina, a ‘female Viagra’, currently being studied
Credit: Aleksandar Todorovic - Fotolia.com

Tefina, the first testosterone based intranasal gel, has been in part developed by the ULg's Galenic Pharmacy Laboratory. It is currently at the stage of testing before being marketed by the Canadian company, Trimel Pharmaceuticals.

The University of Liège's Galenic pharmacy laboratory, directed by Professor Brigitte Evrard, is contributing to the development of the Tefina gel, the first testosterone based intranasal gel. It should be injected, in the form of a , one to two hours before . The nose being an organ rich in , it enables a rapid and targeted absorption of the .

The Liège researchers have been working jointly for two years with the Canadian company, Trimel Pharmaceuticals in the context of developing Tefina. This new drug, which constitutes treatment for female anorgasmia – the impossibility of having an orgasm due to organic, behavioural or psychological reasons – is currently undergoing phase 2 clinical trials in the United States, Canada and Australia. The Canadian company which wants to launch on the market a treatment capable of stimulating desire in women, turned to the Liège laboratory to optimise the product

The University of Liège's Galenic pharmacy laboratory thus developed the composition and formula of an intranasal gel so that a sufficient quantity of testosterone can be administered in a single dose, whilst maintaining the integrity of the nasal epithelium. To ensure optimal activity of the active ingredient it was necessary to solubilise and stabilise it, which proved a genuine challenge for the researchers. The was also studied at the laboratory, which is known for innovating and optimising industrial drug manufacturing processes.

add to favorites email to friend print save as pdf

Related Stories

'Viagra for women' being trialed

Oct 29, 2012

Reaching orgasm remains elusive for nearly 30 per cent of women, but a new ad hoc treatment currently under trial, may drastically reduce that number.

Recommended for you

Supermaterial gives rejected drugs a new chance

6 hours ago

More than 80 percent of all drug candidates in the pharma R&D suffer from poor solubility and are therefore rejected early in the drug discovery process. Now Uppsala University researchers show that the new ...

Risk of antibiotic overuse in aged care settings

Jul 21, 2014

Antibiotics are being overused in residential aged care facilities (RACFs), and more integrated efforts to improve antibiotic prescribing practices need to be introduced, researchers say. 

Ruconest approved for rare genetic disease

Jul 17, 2014

(HealthDay)—Ruconest has been approved by the U.S. Food and Drug Administration to treat hereditary angioedema, a genetic disease that leads to sudden and potentially fatal swelling of the hands, feet, limbs, face, intestinal ...

NIH system to monitor emerging drug trends

Jul 17, 2014

An innovative National Drug Early Warning System (NDEWS) is being developed to monitor emerging trends that will help health experts respond quickly to potential outbreaks of illicit drugs such as heroin and to identify increased ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Tausch
1 / 5 (2) Nov 19, 2012
A new twist to all men are created equal.
Sexual 'equality'?
Oops. Strictly business here.
No selfless, starry-eyed ideals to propagate.